The ARHGEF6 Knockout HT29 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from the human colorectal adenocarcinoma cell line HT29, engineered to disrupt the ARHGEF6 gene locus. This heterogeneous population of loss-of-function variants provides a robust model system for interrogating the cellular consequences of impaired ARHGEF6-mediated signaling without the clonal selection biases inherent to monoclonal lines. The pool retains the genetic diversity of CRISPR-edited lineages, enabling researchers to assess average phenotypic outcomes while minimizing off-target artifacts through population-level averaging. As a validated tool, these cells are suited for applications requiring ablation of ARHGEF6-dependent pathways in an intestinal epithelial context.
HT29 cells were originally isolated from a primary colorectal adenocarcinoma of a 44-year-old female patient and have since become a cornerstone model for intestinal epithelial biology and colorectal cancer research. They exhibit adherent epithelial monolayer morphology and harbor well-characterized mutations in APC, TP53, and KRAS pathways that mirror key oncogenic drivers of colorectal tumorigenesis. The cells maintain the capacity for spontaneous differentiation into enterocyte-like phenotypes under appropriate culture conditions, providing a versatile platform for studying epithelial polarity, barrier function, and oncogenic transformation. Their genetic and phenotypic stability over passages further supports reproducible experimental outcomes in knockout studies.
The ARHGEF6 gene encodes a Rac1/Cdc42 guanine nucleotide exchange factor (GEF) that catalyzes the exchange of GDP for GTP on these small GTPases, thereby activating them. ARHGEF6 function is stimulated by upstream mediators including integrin receptors, PDGF receptor, EGF receptor, Src kinase, and PI3K, linking extracellular cues to cytoskeletal reorganization. Upon activation, ARHGEF6 promotes GTP-loading of Rac1 and Cdc42, which engage downstream effectors such as PAK1, the WAVE complex, and the Arp2/3 complex to drive actin polymerization and lamellipodia formation. Concurrently, the LIM kinase?Ccofilin axis is modulated to facilitate actin treadmilling. ARHGEF6 interacts with focal adhesion adaptors GIT1, paxillin, and Par3, coupling Rho GTPase signaling to cell?Cmatrix adhesion sites and directional migration.
Disruption of ARHGEF6 in HT29 cells impairs the Rac1/Cdc42 signaling axis that governs actin dynamics, cell adhesion, and migration??processes fundamentally dysregulated in colorectal cancer progression and metastasis. This model enables dissection of ARHGEF6-dependent mechanisms in an epithelial tumor background, allowing investigation of how integrin-to-GTPase communication modulates invasive properties and anoikis resistance. It further serves as a platform for evaluating therapeutic strategies targeting Rho GTPase pathways, especially given the role of ARHGEF6 in X-linked intellectual disability and cancer cell dissemination. The polyclonal format recapitulates heterogeneous knockout efficiencies often encountered in pooled CRISPR screens, lending translational relevance.
The ARHGEF6 Knockout HT29 Polyclonal Cells are designed for a spectrum of experimental applications, including Western blotting and RT-qPCR for confirming gene disruption, immunofluorescence microscopy to visualize actin cytoskeletal alterations, and scratch wound or Transwell assays to quantify migration and invasion defects. Biochemical readouts such as Rac1/Cdc42 activation pulldown and phospho-PAK1 analysis allow direct assessment of GTPase signaling status. These cells support colorectal cancer research, signal transduction studies, cytoskeletal dynamics analyses, and drug response profiling, offering a versatile in vitro model. For additional details, please contact Ascent Research.
